- Published on
Emergency and Acute Medicine-Gillian–Barré Syndrome
Basics Description
Guillain–Barré syndrome (GBS) is a group of peripheral nerve disorders characterized by autoimmune-mediated demyelination and axonal degeneration of peripheral nerves, leading to acute ascending paralysis. The disease involves both humoral and cellular immune mechanisms and is the leading cause of acute flaccid paralysis worldwide since the advent of polio vaccination. It is often triggered by a preceding bacterial or viral infection and has an increasing incidence with advancing age and male gender. The average incidence is approximately 1.1 per 100,000 persons per year. Weakness typically reaches its maximum severity within 2–4 weeks, followed by spontaneous recovery over weeks to months. About 80% of patients achieve full recovery at 1 year, 20% are unable to walk at 6 months, and approximately 5% die from complications such as pulmonary embolism, infection, or cardiac arrhythmias.
The most common subtype is acute inflammatory demyelinating polyradiculoneuropathy (AIDP), accounting for about 90% of cases. Other forms include acute motor axonal neuropathy (AMAN), acute motor sensory axonal neuropathy (AMSAN), acute panautonomic neuropathy, and Miller Fisher syndrome. These variants differ in pathophysiology, clinical features, and recovery patterns.
Etiology
GBS is most commonly postinfectious, with approximately two-thirds of patients reporting an antecedent illness, usually respiratory or gastrointestinal, occurring 1–3 weeks before neurologic symptoms. Different autoantibodies are associated with different subtypes. Campylobacter jejuni is the most common bacterial trigger, while cytomegalovirus is the most frequent viral antecedent. Other associated infections include Epstein–Barr virus, varicella-zoster virus, HIV, and Mycoplasma pneumoniae. A causal relationship with vaccines is not well supported, aside from a slight increased risk noted with the 1976 swine influenza vaccine.
Diagnosis Signs And Symptoms
Patients typically present with rapidly progressive, symmetric, ascending weakness. Sensory symptoms are usually mild or absent, though paresthesias of the fingers or toes may occur. Pain is common, especially involving the pelvis, shoulder girdle, or posterior thighs. Cranial nerve involvement may lead to dysphagia, facial weakness, or ophthalmoplegia. Autonomic dysfunction can manifest as blood pressure instability, cardiac dysrhythmias, ileus, or urinary retention. Respiratory insufficiency occurs in approximately 25% of patients. Progression beyond 8 weeks suggests an alternative diagnosis such as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
Diagnosis Tests And Interpretation
Diagnosis is primarily clinical. Laboratory and imaging studies support the diagnosis and help exclude other conditions. Cerebrospinal fluid analysis typically shows albuminocytologic dissociation, with elevated protein and few or no white blood cells, often becoming apparent after 7–10 days. A CSF white blood cell count greater than 10–50 cells/mm³ suggests an alternative diagnosis. Electrolytes may reveal hyponatremia due to SIADH. CT or MRI is used to rule out spinal cord compression. Electrophysiologic studies demonstrate abnormalities consistent with demyelination or axonal injury and are confirmatory.
Differential Diagnosis
The differential diagnosis includes other polyneuropathies, spinal cord disorders, neuromuscular junction diseases, muscle disorders, metabolic abnormalities, and functional neurologic conditions.
Treatment Pre Hospital
Early attention to airway protection is essential due to the risk of rapid respiratory compromise.
Initial Stabilization Therapy
Careful and repeated airway assessment is critical, as progression to respiratory failure can occur quickly.
Ed Treatment Procedures
Approximately 30% of patients require ventilatory support, sometimes within 24–48 hours of symptom onset. Frequent monitoring of respiratory function using forced vital capacity (FVC) or negative inspiratory force (NIF) is recommended. ICU admission is indicated if FVC is less than 20 mL/kg or NIF is less than 30 cm H₂O, with intubation strongly considered if FVC drops below 15 mL/kg. Autonomic instability should be closely monitored. Early neurology consultation is essential.
Medication
Disease-modifying therapy includes plasmapheresis or intravenous immunoglobulin (IVIG), initiated in consultation with neurology. IVIG is typically given at 400 mg/kg/day for 5 days. Pain management may include acetaminophen, NSAIDs, or gabapentin. Corticosteroids are not beneficial and may delay recovery.
Follow-Up Disposition
All patients with suspected or confirmed GBS require hospital admission for close monitoring. ICU admission is necessary for those with respiratory compromise, autonomic dysfunction, or rapidly progressive weakness. Discharge should only be considered after neurologic consultation.
Follow-Up Recommendations
Ongoing follow-up is determined by neurology. Factors associated with poorer outcomes include advanced age, longer time to symptom nadir, need for mechanical ventilation, and preceding diarrheal illness, particularly due to C. jejuni.
Clinical Insights And Common Diagnostic Errors
Frequent assessment of respiratory parameters such as FVC and NIF is essential to anticipate airway compromise. A CSF white blood cell count exceeding 10–50 cells/mm³ should prompt reconsideration of the diagnosis. Common errors include failing to obtain appropriate neuroimaging to exclude alternative causes, delaying neurology consultation, and not admitting or closely observing patients with suspected GBS.
Basics Description
Guillain–Barré syndrome (GBS) is a group of peripheral nerve disorders characterized by autoimmune-mediated demyelination and axonal degeneration of peripheral nerves, leading to acute ascending paralysis. The disease involves both humoral and cellular immune mechanisms and is the leading cause of acute flaccid paralysis worldwide since the advent of polio vaccination. It is often triggered by a preceding bacterial or viral infection and has an increasing incidence with advancing age and male gender. The average incidence is approximately 1.1 per 100,000 persons per year. Weakness typically reaches its maximum severity within 2–4 weeks, followed by spontaneous recovery over weeks to months. About 80% of patients achieve full recovery at 1 year, 20% are unable to walk at 6 months, and approximately 5% die from complications such as pulmonary embolism, infection, or cardiac arrhythmias.
The most common subtype is acute inflammatory demyelinating polyradiculoneuropathy (AIDP), accounting for about 90% of cases. Other forms include acute motor axonal neuropathy (AMAN), acute motor sensory axonal neuropathy (AMSAN), acute panautonomic neuropathy, and Miller Fisher syndrome. These variants differ in pathophysiology, clinical features, and recovery patterns.
Etiology
GBS is most commonly postinfectious, with approximately two-thirds of patients reporting an antecedent illness, usually respiratory or gastrointestinal, occurring 1–3 weeks before neurologic symptoms. Different autoantibodies are associated with different subtypes. Campylobacter jejuni is the most common bacterial trigger, while cytomegalovirus is the most frequent viral antecedent. Other associated infections include Epstein–Barr virus, varicella-zoster virus, HIV, and Mycoplasma pneumoniae. A causal relationship with vaccines is not well supported, aside from a slight increased risk noted with the 1976 swine influenza vaccine.
Diagnosis Signs And Symptoms
Patients typically present with rapidly progressive, symmetric, ascending weakness. Sensory symptoms are usually mild or absent, though paresthesias of the fingers or toes may occur. Pain is common, especially involving the pelvis, shoulder girdle, or posterior thighs. Cranial nerve involvement may lead to dysphagia, facial weakness, or ophthalmoplegia. Autonomic dysfunction can manifest as blood pressure instability, cardiac dysrhythmias, ileus, or urinary retention. Respiratory insufficiency occurs in approximately 25% of patients. Progression beyond 8 weeks suggests an alternative diagnosis such as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
Diagnosis Tests And Interpretation
Diagnosis is primarily clinical. Laboratory and imaging studies support the diagnosis and help exclude other conditions. Cerebrospinal fluid analysis typically shows albuminocytologic dissociation, with elevated protein and few or no white blood cells, often becoming apparent after 7–10 days. A CSF white blood cell count greater than 10–50 cells/mm³ suggests an alternative diagnosis. Electrolytes may reveal hyponatremia due to SIADH. CT or MRI is used to rule out spinal cord compression. Electrophysiologic studies demonstrate abnormalities consistent with demyelination or axonal injury and are confirmatory.
Differential Diagnosis
The differential diagnosis includes other polyneuropathies, spinal cord disorders, neuromuscular junction diseases, muscle disorders, metabolic abnormalities, and functional neurologic conditions.
Treatment Pre Hospital
Early attention to airway protection is essential due to the risk of rapid respiratory compromise.
Initial Stabilization Therapy
Careful and repeated airway assessment is critical, as progression to respiratory failure can occur quickly.
Ed Treatment Procedures
Approximately 30% of patients require ventilatory support, sometimes within 24–48 hours of symptom onset. Frequent monitoring of respiratory function using forced vital capacity (FVC) or negative inspiratory force (NIF) is recommended. ICU admission is indicated if FVC is less than 20 mL/kg or NIF is less than 30 cm H₂O, with intubation strongly considered if FVC drops below 15 mL/kg. Autonomic instability should be closely monitored. Early neurology consultation is essential.
Medication
Disease-modifying therapy includes plasmapheresis or intravenous immunoglobulin (IVIG), initiated in consultation with neurology. IVIG is typically given at 400 mg/kg/day for 5 days. Pain management may include acetaminophen, NSAIDs, or gabapentin. Corticosteroids are not beneficial and may delay recovery.
Follow-Up Disposition
All patients with suspected or confirmed GBS require hospital admission for close monitoring. ICU admission is necessary for those with respiratory compromise, autonomic dysfunction, or rapidly progressive weakness. Discharge should only be considered after neurologic consultation.
Follow-Up Recommendations
Ongoing follow-up is determined by neurology. Factors associated with poorer outcomes include advanced age, longer time to symptom nadir, need for mechanical ventilation, and preceding diarrheal illness, particularly due to C. jejuni.
Clinical Insights And Common Diagnostic Errors
Frequent assessment of respiratory parameters such as FVC and NIF is essential to anticipate airway compromise. A CSF white blood cell count exceeding 10–50 cells/mm³ should prompt reconsideration of the diagnosis. Common errors include failing to obtain appropriate neuroimaging to exclude alternative causes, delaying neurology consultation, and not admitting or closely observing patients with suspected GBS.
0 Comments
